Pharmacological properties of revefenacin (TD‐4208), a novel, nebulized long‐acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues

Revefenacin (TD‐4208) is a novel, long‐acting, and lung‐selective muscarinic cholinergic receptor (mAChR) antagonist in development as a nebulized inhalation solution for the treatment of chronic obstructive pulmonary disease (COPD) patients. This study evaluated the pharmacology of revefenacin at h...

Descripción completa

Detalles Bibliográficos
Autores principales: Hegde, Sharath S., Pulido‐Rios, M. Teresa, Luttmann, Mark A., Foley, James J., Hunsberger, Gerald E., Steinfeld, Tod, Lee, TaeWeon, Ji, Yuhua, Mammen, Mathai M., Jasper, Jeffrey R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927803/
https://www.ncbi.nlm.nih.gov/pubmed/29736245
http://dx.doi.org/10.1002/prp2.400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927803/
https://www.ncbi.nlm.nih.gov/pubmed/29736245
http://dx.doi.org/10.1002/prp2.400

Ejemplares similares